Browse articles on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Glaucoma Section Editor Nathan Radcliffe, MD, writes about the “chaotic events” that often thwart glaucoma patient care, how he thinks can help his patients become “antifragile,” how they can “grow from unpredictability and chaos.”
New innovations are entering the glaucoma space on a regular basis, but how do physicians discern whether (and when) to adopt them and what is that process like? Two physicians shared their considerations and experiences with bringing new techniques and technologies into practice.
Tube shunts still have important applications for glaucoma patients today and are often used for more severe disease. When categorizing tubes shunts, there are valved or non-valved options. Three physicians discussed the available non-valved tube implants, particularly how a newer option compares to older.
Laurie Guest, CSP, CPAE, gave the keynote talk at the ASOA Monday General Session of the 2022 Annual Meeting. This article recapped her presentation, “Life in the Espresso Lane: How to be Smooth, Bold, and Balanced in a Fast-paced World.”
Corrine Wohl, MHSA, COE, and John Pinto discussed the hard reality of when a trusted administrator leaves the practice. This is something practices should be prepared for—and they have seven tips to help.
The pandemic served as the catalyst for workforce reform, reform that likely had been building behind the scenes as technology has advanced and workplace culture evolved. With this evolution, there are opportunities to embrace the current workforce challenges. William Rabourn Jr. shared his thoughts in this quarterly column.
EyeWorld honors the lives of ophthalmologists who have died recently with recognition in this space.
“X-Rounds: Refractive Cataract Surgery to the Max” is a fast-paced session at the ASCRS Annual Meeting where members of the panel presented their answer to a question or thoughts on a topic in 2.5 minutes or less. The audience then voted for their favorite in each section.
Restasis (cyclosporine ophthalmic emulsion) was developed by Allergan and approved by the U.S. FDA in 2003. Now, after nearly 2 decades since its approval as a brand name drug indicated for symptoms of dry eye, a generic version of Restasis has been approved. It was a “long time coming,” according to Henry Perry, MD.
Attendees of the ASCRS Annual Meeting will have the opportunity to attend a new ASCRS Satellite CME Program, “Diversity, Equity and Inclusion: When Identifying the Problem Is Not Enough, Leadership Must Take Action,” on Monday from 8:00–9:30 a.m. Moderators Ann Caroline Fisher, MD, and Leon Herndon Jr., MD, spoke to EyeWorld about what to expect at the program that focuses on a social justice issue.